Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4

Shinji Yamada, Shunsuke Itai, Mika K. Kaneko, Yukinari Kato

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Programmed cell death-ligand 1 (PD-L1), which is a ligand of programmed cell death-1 (PD-1), is a type I transmembrane glycoprotein that is expressed on antigen-presenting cells and several tumor cells, including melanoma and lung cancer cells. There is a strong correlation between human PD-L1 (hPD-L1) expression on tumor cells and negative prognosis in cancer patients. In this study, we produced a novel anti-hPD-L1 monoclonal antibody (mAb), L1Mab-4 (IgG2b, kappa), using cell-based immunization and screening (CBIS) method and investigated hPD-L1 expression in oral cancers. L1Mab-4 reacted with oral cancer cell lines (Ca9-22, HO-1-u-1, SAS, HSC-2, HSC-3, and HSC-4) in flow cytometry and stained oral cancers in a membrane-staining pattern. L1Mab-4 stained 106/150 (70.7%) of oral squamous cell carcinomas, indicating the very high sensitivity of L1Mab-4. These results indicate that L1Mab-4 could be useful for investigating the function of hPD-L1 in oral cancers.

Original languageEnglish
Pages (from-to)123-128
Number of pages6
JournalBiochemistry and Biophysics Reports
Publication statusPublished - 2018 Mar


  • Monoclonal antibody
  • Oral cancer
  • Programmed cell death-ligand 1


Dive into the research topics of 'Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4'. Together they form a unique fingerprint.

Cite this